Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

October 18, 2021

Study Completion Date

June 14, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

belantamab mafodotin

belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.

DRUG

Pembrolizumab

Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.

Trial Locations (12)

12200

GSK Investigational Site, Berlin

20246

GSK Investigational Site, Hamburg

28204

GSK Investigational Site, Charlotte

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

30322

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

37007

GSK Investigational Site, Salamanca

46202

GSK Investigational Site, Indianapolis

53792

GSK Investigational Site, Madison

T2N 2T9

GSK Investigational Site, Calgary

M5G 2M9

GSK Investigational Site, Toronto

08916

GSK Investigational Site, Badalona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT03848845 - Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter